Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 18/20 | 0.52 |
| ▸ | AXL | P30530 | 3/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | MST1R | Q04912 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30616271 | 1.00 | MET (0.52) | METAXLKDRKITFLT4 | |
| SCHEMBL30616269 | 0.85 | MET (0.54) | METAXLKDRKITFLT4 | |
| SCHEMBL21201049 | 0.85 | MET (0.54) | METAXLKDRKITFLT4 | |
| SCHEMBL29812277 | 0.83 | AXL (0.39) | METAXLKDRKITFLT4 | |
| SCHEMBL23146988 | 0.83 | AXL (0.39) | METAXLKDRKITFLT4 | |
| SCHEMBL21201172 | 0.83 | MET (0.49) | METAXLKDRKITFLT4 | |
| SCHEMBL30616303 | 0.83 | MET (0.49) | METAXLKDRKITFLT4 | |
| SCHEMBL30066135 | 0.83 | AXL (0.55) | METAXLKDRPDGFRA | |
| SCHEMBL1132352 | 0.83 | AXL (0.55) | METAXLKDRPDGFRA | |
| SCHEMBL199658 | 0.80 | TRPA1 (0.53) | METAXLKDRPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4647127-A2 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | Exelixis, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-3743070-B1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | EXELIXIS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| CN-117820226-A | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117624045-A | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117603138-A | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-02-27 | — | — | CN | disclosed |
| US-20240043414-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2024-02-08 | — | — | US | disclosed |
| CN-117402114-A | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-111757735-B | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2023-09-22 | — | — | CN | disclosed |
| US-11542259-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11542259-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210040076-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2021-02-11 | — | — | US | disclosed |
| US-20210040076-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2021-02-11 | — | — | US | disclosed |
| EP-3743070-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | Exelixis, Inc. (US) | 2020-12-02 | — | — | EP | disclosed |
| CN-111757735-A | Compounds for the treatment of kinase-dependent disorders | 埃克塞里艾克西斯公司 | 2020-10-09 | — | — | CN | disclosed |
| WO-2019148044-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | EXELIXIS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| WO-2019148044-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | EXELIXIS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542259-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, MAP3K6, MAP3K1 | MET 154/4885AXL 269/4885KDR 237/4885 |
| US-20210040076-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, MAP3K6, MAP3K1 | MET 154/4885AXL 269/4885KDR 237/4885 |
| US-20240043414-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, MAP3K6, MAP3K1 | MET 154/4885AXL 269/4885KDR 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.